NO20015374D0 - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20015374D0
NO20015374D0 NO20015374A NO20015374A NO20015374D0 NO 20015374 D0 NO20015374 D0 NO 20015374D0 NO 20015374 A NO20015374 A NO 20015374A NO 20015374 A NO20015374 A NO 20015374A NO 20015374 D0 NO20015374 D0 NO 20015374D0
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO20015374A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015374L (no
Inventor
Marcel Linschoten
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015374D0 publication Critical patent/NO20015374D0/no
Publication of NO20015374L publication Critical patent/NO20015374L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09Diamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
NO20015374A 1999-05-03 2001-11-02 Nye forbindelser NO20015374L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds
PCT/SE2000/000846 WO2000066550A1 (en) 1999-05-03 2000-05-03 New compounds

Publications (2)

Publication Number Publication Date
NO20015374D0 true NO20015374D0 (no) 2001-11-02
NO20015374L NO20015374L (no) 2001-11-02

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015374A NO20015374L (no) 1999-05-03 2001-11-02 Nye forbindelser

Country Status (23)

Country Link
US (2) US7354895B1 (zh)
EP (1) EP1180099A1 (zh)
JP (1) JP4270759B2 (zh)
KR (1) KR20020010631A (zh)
CN (1) CN1358187A (zh)
AR (1) AR028826A1 (zh)
AU (1) AU4447100A (zh)
BR (1) BR0010256A (zh)
CA (1) CA2371215A1 (zh)
CZ (1) CZ20013931A3 (zh)
EE (1) EE200100573A (zh)
HK (1) HK1042493A1 (zh)
HU (1) HUP0202379A3 (zh)
IL (1) IL145953A0 (zh)
IS (1) IS6141A (zh)
MX (1) MXPA01011043A (zh)
NO (1) NO20015374L (zh)
PL (1) PL356140A1 (zh)
SE (1) SE9901572D0 (zh)
SK (1) SK15662001A3 (zh)
TR (1) TR200103144T2 (zh)
WO (1) WO2000066550A1 (zh)
ZA (2) ZA200108967B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 b 저해활성을 갖는 포스폰산 유도체
EA005532B1 (ru) * 2000-08-17 2005-04-28 Пфайзер Инк. Замещенные имидазолы в качестве ингибиторов активированной формы активируемого тромбином ингибитора фибринолиза (tafia)
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
JP2005516972A (ja) 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP1467731A1 (en) * 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
CA2714873A1 (en) 2002-03-21 2003-10-02 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
CN113395996B (zh) * 2019-02-08 2024-05-28 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
CA2124792C (en) * 1991-12-17 2000-07-04 Ann D. Geddes Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 7−(n−置換アミノ)−2−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
SK115799A3 (en) 1997-02-27 2000-09-12 American Cyanamid Co N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL ORì (54) SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 b 저해활성을 갖는 포스폰산 유도체

Also Published As

Publication number Publication date
KR20020010631A (ko) 2002-02-04
JP2002543179A (ja) 2002-12-17
AR028826A1 (es) 2003-05-28
SK15662001A3 (sk) 2002-09-10
AU4447100A (en) 2000-11-17
HUP0202379A2 (hu) 2002-12-28
CA2371215A1 (en) 2000-11-09
MXPA01011043A (es) 2002-06-04
TR200103144T2 (tr) 2004-11-22
EE200100573A (et) 2003-02-17
CZ20013931A3 (cs) 2002-04-17
SE9901572D0 (sv) 1999-05-03
EP1180099A1 (en) 2002-02-20
CN1358187A (zh) 2002-07-10
NO20015374L (no) 2001-11-02
JP4270759B2 (ja) 2009-06-03
US7423012B2 (en) 2008-09-09
WO2000066550A1 (en) 2000-11-09
WO2000066550A8 (en) 2001-01-25
PL356140A1 (en) 2004-06-14
US20060079484A1 (en) 2006-04-13
HK1042493A1 (zh) 2002-08-16
ZA200108967B (en) 2003-01-30
ZA200108966B (en) 2003-01-30
BR0010256A (pt) 2002-02-13
HUP0202379A3 (en) 2003-04-28
US7354895B1 (en) 2008-04-08
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01

Similar Documents

Publication Publication Date Title
NO20014518D0 (no) Nye forbindelser
DK1202994T3 (da) Nye forbindelser
NO20021436L (no) Nye forbindelser
NO20026064L (no) Nye forbindelser
NO20023934L (no) Nye forbindelser
NO20033715L (no) Nye sammensetninger
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
NO20015383L (no) Nye forbindelser
NO20020810D0 (no) Nye fenylpiperaziner
NO20025151D0 (no) Nye forbindelser
DK1237857T3 (da) Nye Phenalkyloxyphenylderivater
NO20031141D0 (no) Nye forbindelser
NO20015074L (no) Nye sammensetninger
NO20010860D0 (no) Nye forbindelser
NO20010861D0 (no) Nye forbindelser
NO20026162L (no) Nye forbindelser
NO20026081D0 (no) Nye forbindelser
NO20030274D0 (no) Nye aryleten-sulfonamider
NO995945D0 (no) Nye forbindelser
NO20015374L (no) Nye forbindelser
NO20014629L (no) Nye forbindelser
NO20022927D0 (no) Substituerte pyrrazoler
NO20016273L (no) Nye forbindelser
NO20010584D0 (no) Nye forbindelser
NO20011262D0 (no) Nye forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application